How does emerging patent case law in the US and Europe affect precision medicine?
Open accessThe DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Abstract
How will today’s patent law affect tomorrow’s innovation in the areas of biomarkers and nature-based products; diagnostics; and algorithms, big data and AI?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In the US, recent patent law decisions made it harder—but not impossible—to obtain patent protection for precision medicine inventions, whereas in Europe, a less stringent standard of patent eligibility is applied such as for nature-based biomarkers [122].”
From Ethical and legal challenges of artificial intelligence-driven healthcare (2020) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell-free DNA Analysis for Noninvasive Examination of Trisomy
Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407349 · Cited by 817
Agreement on trade-related aspects of intellectual property rights
Heath, G. (2000) · Comparative law yearbook of international business · Cited by 469
Objective biomarkers of balance and gait for Parkinson's disease using body‐worn sensors
Horak, F. B., & Mancini, M. (2013) · Movement Disorders · doi:10.1002/mds.25684 · Cited by 255
The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology
Cagney, D. N., Sul, J., Huang, R. Y., Ligon, K. L., Wen, P. Y., & Alexander, B. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox242 · Cited by 214
Waste, Leaks, and Failures in the Biomarker Pipeline
Ioannidis, J. P. A., & Bossuyt, P. M. M. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2016.254649 · Cited by 172
The History of Patenting Genetic Material
Sherkow, J. S., & Greely, H. T. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054731 · Cited by 63
Patentability of Genes: A European Union PerspectivePreprint
Cole, P. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a020891 · Cited by 37
涼子, 井. (2013) · ジュリスト = Monthly jurist · Cited by 35
After Myriad, what makes a gene patent claim 'markedly different' from nature?
Aboy, M., Liddicoat, J., Liddell, K., Jordan, M., & Crespo, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3953 · Cited by 21
Self-citationMyriad's impact on gene patents
Aboy, M., Liddell, K., Liddicoat, J., & Crespo, C. (2016) · Nature Biotechnology · doi:10.1038/nbt.3719 · Cited by 19
Self-citation
Research works printed but not linked: 19
- Price, W. N. Harv. J. Law Technol. 28, 419–467 (2015).
- Mayo Collaborative Services v. Prometheus Laboratories, Inc. in S. Ct., Vol. 132 1289 (Supreme Court, 2012).
- Association for Molecular Pathology v. Myriad Genetics, Inc. in S. Ct., Vol. 133 2107 (Supreme Court, 2013).
- Holman, C. M. George Mason Law Rev. 23, 901–940 (2016).
- Schwartz, R. M. & Minssen, T. Intell. Prop. Q. 3, 189–241 (2015).
- Alice Corp. v. CLS Bank International. in S. Ct., Vol. 134 2347 (Supreme Court, 2014).
- Bilski v. Kappos. in S. Ct., Vol. 130 3218 (Supreme Court, 2010).
- Diamond v. Diehr. in S. Ct., Vol. 101 1048 (Supreme Court, 1981).
- Gold, R. E., Cook-Deegan, R. & Bubela, T. Sci. Transl. Med. 5, (192ed9 (2013).
- Ariosa Diagnostics, Inc. v. Sequenom, Inc. in F.3d, Vol. 588 1371 (Federal Circuit, 2015).
- Vanda Pharmaceuticals Inc., v. West-Ward Pharmaceuticals International Ltd. in F.3d, Vol. 887 1117 (Federal Circuit, 2018).
- In re Grams. in F.2d, Vol. 888 835 (Federal Circuit, 1989).
- Gottschalk v. Benson. in S. Ct., Vol. 93 253 (Supreme Court, 1972).
- Parker v. Flook. in S. Ct., Vol. 98 2522 (Supreme Court, 1978).
- McRO, Inc. v. Bandai Namco Games America Inc. in F.3d, Vol. 837 1299 (Federal Circuit, 2016).
- Enfish, LLC v. Microsoft Corp. in F.3d, Vol. 822 1327 (Federal Circuit, 2016).
- FairWarning IP, LLC v. Iatric Systems, Inc. in F.3d, Vol. 839 1089 (Federal Circuit, 2016).
- Illumina, Inc. v. Premaitha Health, Plc. in EWHC, Vol. 2930 (Chancery Division (Patents Court), 2017).
- Minssen, T. & Pierce, J. in Big Data, Health Law, and Bioethics (eds. Cohen, I.G. et al.) (Cambridge Univ. Press, 2018).
Cited by
Ethical and legal challenges of artificial intelligence-driven healthcare
Gerke, S., Minssen, T., & Cohen, G. (2020) · Artificial Intelligence in Healthcare · doi:10.1016/b978-0-12-818438-7.00012-5 · Cited by 1,170
“er—but not impossible—to obtain patent protection for precision medicine inventions, whereas in Europe, a less stringent standard of patent eligibility is applied such as for nature-based biomarkers [122].”
Self-citationEthical and Legal Challenges of Artificial Intelligence-Driven Healthcare
Gerke, S., Minssen, T., & Cohen, I. G. (2020) · doi:10.2139/ssrn.3570129 · Cited by 177
Self-citationGupta, C., Chandrashekar, P. B., Jin, T., He, C., Khullar, S., Chang, Q., & Wang, D. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09438-w · Cited by 76
Aboy, M., Minssen, T., & Kop, M. (2022) · GRURRR. Gewerblicher Rechtsschutz und Urheberrecht, Rechtsprechungs-Report/GRUR-DVD/GRUR-CD/IIC/Gewerblicher Rechtsschutz und Urheberrecht/Gewerblicher Rechtsschutz und Urheberrecht. Internationaler Teil · doi:10.1007/s40319-022-01209-3 · Cited by 63
“22 Minssen et al. (2020), Aboy et al. (2019).”
Self-citationKop, M., Aboy, M., & Minssen, T. (2022) · Journal of Intellectual Property Law & Practice · doi:10.1093/jiplp/jpac060 · Cited by 42
Self-citation
Metadata
- Authors
- Aboy, M., Liddell, K., Crespo, C., Cohen, I. G., Liddicoat, J., Gerke, S., & Minssen, T.
- Affiliations
- University of Cambridge (GB)
- Harvard University (US)
- University of Copenhagen (DK)
- Corresponding author
- Aboy, Mateo
- ORCID
- Venue
- Nature Biotechnology
- Published
- 2019-10
- Volume
- 37
- Issue
- 10
- Pages
- 1118-1125
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2977890762
- Cited by
- 20
- References
- 19
- Citations by year
- 2025: 2 · 2023: 3 · 2022: 7 · 2021: 2 · 2020: 6
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- UTAS Research Repository (submittedVersion)
- bepress Legal Repository (submittedVersion)
- eYLS (Yale Law School) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Novo Nordisk Fonden (NNF17SA0027784)
- Topics
- Physical Sciences › Computer Science › Artificial Intelligence › Law, AI, and Intellectual Property
- Social Sciences › Law › Intellectual Property Law
- Social Sciences › Business, Management and Accounting › Management of Technology and Innovation › Intellectual Property and Patents
- Keywords
- patent law, precision medicine, biomarkers, nature-based products, diagnostics, artificial intelligence, big data, algorithms, patent case law, innovation, United States, Europe
- MeSH terms
- Algorithms, Artificial Intelligence, Biological Products, Europe, Humans, Patents as Topic, United States, Biomarkers, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How does emerging patent case law in the US and Europe affect precision medicine? https://app.cochat.ai/papers/10.1038/s41587-019-0265-1
- The paper
- Aboy, M., Liddell, K., Crespo, C., Cohen, I. G., Liddicoat, J., Gerke, S., & Minssen, T. (2019). How does emerging patent case law in the US and Europe affect precision medicine? Nature Biotechnology. https://doi.org/10.1038/s41587-019-0265-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.